DocGo (DCGO) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue reached $164.9M, up 31% year-over-year, with net income rising to $5.9M and adjusted EBITDA of $17.2M, reflecting strong operational execution and new business momentum.

• Mobile Health Services revenue rose 46% to $116.7M, while Transportation Services increased 6% to $48.2M, driven by government contracts and new business wins.

• Cost controls and improved cash collections contributed to margin expansion and a reduction in operating expenses as a percentage of revenue to 27.7%.

• Launched a Medical Advisory Board and enhanced technology platform to support clinical offerings and research.

• Multiple new contracts signed across payer, provider, hospital, and municipal verticals, including major expansions in care gap closure and mobile health services.

Financial highlights

• Q2 2024 revenue: $164.9M (+31% YoY); net income: $5.9M; adjusted EBITDA: $17.2M; adjusted EBITDA margin: 10.4% (up from 7.3%).

• GAAP gross margin was 31.3%, and adjusted gross margin was 33.9%.

• Cash and equivalents rose to $85.8M at June 30, 2024, from $58.9M at Q1 end.

• Operating cash flow for six months was $26.4M, up from a $12.4M outflow last year; Q2 cash flow from operations exceeded $35M.

• Basic and diluted EPS for Q2 2024 were $0.06.

Outlook and guidance

• 2024 revenue guidance reaffirmed at $600M–$650M; adjusted EBITDA guidance at $65M–$75M.

• Cash flow from operations guidance raised to $80M–$90M for 2024.

• Mobile Health Services revenue expected to decline in H2 2024 as migrant-related projects wind down, despite new project launches.

• Transportation Services expected to maintain growth, supported by increased trip volumes and stable average trip prices.

• 2025 base business projected to grow over 30% with adjusted EBITDA margin above 10%.